Nuvation Bio Inc. (NUVB) Stock Profile — Insider Trades & Financials

Revenue$41.9M

Net Income-$36.6M

EPS$-0.60

Gross Margin0.0%

Market Cap$1.5B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

David Hung

CEO & Executive Director

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The companyâs lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Founded: 2018
Employees: 298
Headquarters: New York, New York, United States

⚡

Core Efficiency

ROE?

-11.97%

ROA?

-6.15%

D/E Ratio?

0.95

Op. Margin?

-81.30%

📊

Profitability Ratios

Net Margin?

-87.40%

Loading company sections...

Nuvation Bio Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness